Placebo News and Research

RSS

$Drug that mimics HDL does not reduce risk of death for heart attack patients with refractory shock$

Drug that mimics HDL does not reduce risk of death for heart attack patients with refractory shock

Patients with acute coronary syndromes (ACS), such as heart attack and recent-onset chest pain, remain at considerable risk of experiencing further serious cardiovascular problems despite improvements in care.

2 Apr 2007

Tilarginine does not reduce risk of death after heart attack

The medication tilarginine, a drug that was believed could be beneficial for patients who develop cardiogenic shock (low blood pressure due to impaired cardiac function) after a heart attack, did not reduce the risk of death up to six months after a heart attack, according to a JAMA study published online March 26.

2 Apr 2007

Effect of Torcetrapib on the progression of coronary atherosclerosis

Investigators report that torcetrapib, a drug that substantially raises high-density lipoprotein cholesterol or HDL (the "good" cholesterol), did not slow the progression of plaque buildup in the coronary arteries as measured using an ultrasound probe (IVUS).

2 Apr 2007

Long-term low to moderate doses of aspirin beneficial for women

Women who take low to moderate doses of aspirin have a reduced risk of death from any cause, and especially heart disease related deaths, according to a report in the March 26 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

2 Apr 2007

Reconstituted HDL may have some benefit in coronary atherosclerosis

Preliminary research suggests that use of reconstituted HDL may have some benefit in coronary atherosclerosis, according to a JAMA study published online March 26.

2 Apr 2007

Costs due to complications from preterm birth are staggering

In Canada, outlays for specialized care of surviving preterm infants are estimated to be almost $2 billion per year.

2 Apr 2007

Study results on bifeprunox in patients with schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week.

2 Apr 2007

Treatment options for bipolar disorder

For depressed people with bipolar disorder who are taking a mood stabilizer, adding an antidepressant medication is no more effective than a placebo (sugar pill), according to results published online on March 28, 2007 in the New England Journal of Medicine.

1 Apr 2007

Hearing-protection tablet helps soldiers defend against hearing loss

Soldiers exposed to the deafening din of battle have little defense against hearing loss, and are often reluctant to wear protective gear like ear plugs that could make them less able to react to danger.

31 Mar 2007

Novel anti-oxidant and anti-inflammatory agent reduces coronary events

Heart attacks are caused by a build-up and instability of plaque in the coronary arteries, which is often a result of chronic inflammation of the blood vessel walls.

31 Mar 2007

FDA announces marketing halt for GI drug, Zelnorm

The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug. Novartis has agreed to voluntarily suspend marketing of the drug in the United States.

30 Mar 2007

New treatments and interventions for chronically impaired cardiac patients

Whether a patient is awaiting a heart transplant or living with chronic heart failure, cardiologists are continuously looking for new therapies that address short-term and/or long-term needs of chronically impaired cardiac patients.

30 Mar 2007

Crateagus extract postpones cardiac events in patients with congestive heart failure

An herbal medicinal substance, Crataegus Extract WS:1442, safely extends the lives of congestive heart failure patients already receiving pharmacological treatment for the disease, according to a study presented at the American College of Cardiology's 56th Annual Scientific Session.

30 Mar 2007